New Front-Runner Emerges In China mRNA Booster Race

CSPC Reveals Promising Results

 
• By Dexter Jie Yan

China's CSPC Pharmaceutical Group surprises by announcing investigator-initiated trial results for SYS6006, its mRNA COVID-19 vaccine candidate against the Omicron variant.

China domestic frontrunner mRNA vaccine
CSPC progressing domestic and international multicenter clinical studies of SYS6006. • Source: Shutterstock

More from China

More from Focus On Asia